XBiotech Inc. (XBIT) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, XBiotech Inc. (NASDAQ: XBIT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.94 (-2.51% 1D, market cap $59.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, XBIT ranks #616 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VRCA (Verrica Pharmaceuticals Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $58.8M) and RFL (Rafael Holdings Inc. (Class B)) posts a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $58.2M). Among the 5-stock peer group, XBIT leads on earnings multiple (N/A) while XBIT leads on capital efficiency (-35.0% ROIC).
Per XBIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626878), XBiotech Inc. generated $0 in revenue, -$45.5M in net income, and -$40.2M in free cash flow against $150.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
FRED Regime × Technicals: 9% of 52W Range • RSI-14 at 33.8 (NEUTRAL RANGE)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
While XBIT currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.15) and Max Pain ($2.04) forces dealer call-delta covering toward $3.61.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
XBiotech Inc. (XBIT) dropped -2.51% to $1.94, trading at 9% of its 52-week range ($1.8 – $3.44). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
AUSTIN, Texas, Oct. 23, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shiva
XBiotech Inc. (NASDAQ: XBIT) today announced that its Board of Directors have elected Jan-Paul Simard to serve as Co-Chief Executive Officer alongside CEO Dr. Sushma Shivaswamy, effective Oct. 23, 2026.
Investigator-sponsored study funded by the French National Cancer Institute (INCa) meets pre-specified primary efficacy success criterion with 61.3% 12-month overall survival. Exploratory Subgroup analysis reveals signif
XBiotech Inc. (NASDAQ: XBIT) today announced positive final efficacy results from the randomized Phase II portion of the multicenter TASKIN clinical trial. The investigator-sponsored study—funded by the French National
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on XBIT today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for XBIT. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, XBiotech Inc. (XBIT) ranks #616 by composite RQD confidence (37/100, grade D-) and #725 by equity capitalization ($59.1M). Within this direct 5-issuer industry benchmark cohort, XBIT leads on earnings valuation at N/A trailing P/E, while XBIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. APLM currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with XBIT at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| XBIT
ACTIVE
XBiotech Inc. | D- | 37/100 | — | — | -35.0% | -2.51% | $59.1M | Benchmark Subject |
| VRCA Verrica Pharmaceuticals Inc. | D | 44/100 | — | — | -35.0% | -1.72% | $58.8M | /vrca-vs-xbit → |
| RFL Rafael Holdings Inc. (Class B) | E | 16/100 | — | — | -35.0% | -7.44% | $58.2M | /rfl-vs-xbit → |
| APLM Apollomics Inc. (Class A) | C | 62/100 | — | — | — | +4.16% | $60.2M | /aplm-vs-xbit → |
| BOLD Boundless Bio Inc. | D- | 41/100 | — | — | -35.0% | -0.80% | $57.3M | /bold-vs-xbit → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), XBiotech Inc. (XBIT) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$45.5M, operating cash flow of -$39.9M, and free cash flow of -$40.2M (-24.6% YoY). On the balance sheet, XBIT closed FY2025 with $150.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$45.5M | -$39.9M | -$40.2M | $150.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$38.5M | -$31.0M | -$32.3M | $199.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$24.6M | -$18.7M | -$18.7M | — | — |
As of 2026-11-02, XBiotech Inc. (NASDAQ: XBIT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.94 (-2.51% 1D, market cap $59.1M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, XBIT ranks #616 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), XBIT carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VRCA (Verrica Pharmaceuticals Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $58.8M) and RFL (Rafael Holdings Inc. (Class B)) posts a E grade (16/100 RQD, P/E N/A, ROIC -35.0%, cap $58.2M). Among the 5-stock peer group, XBIT leads on earnings multiple (N/A) while XBIT leads on capital efficiency (-35.0% ROIC).
Per XBIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001626878), XBiotech Inc. generated $0 in revenue, -$45.5M in net income, and -$40.2M in free cash flow against $150.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
XBIT last traded at $1.94 (-2.51% on volume of 73,986 shares), positioning the stock -9.77% below its 50-day simple moving average ($2.15) and -16.38% below its 200-day simple moving average ($2.32). Across its 52-week range of $1.80 to $3.44, XBIT sits at the 8.5% percentile with a 14-day RSI of 33.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.0% ($1.73 to $2.15).
Why XBIT Stock dropped -2.51% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).